CL2007002499A1 - Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. - Google Patents

Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.

Info

Publication number
CL2007002499A1
CL2007002499A1 CL200702499A CL2007002499A CL2007002499A1 CL 2007002499 A1 CL2007002499 A1 CL 2007002499A1 CL 200702499 A CL200702499 A CL 200702499A CL 2007002499 A CL2007002499 A CL 2007002499A CL 2007002499 A1 CL2007002499 A1 CL 2007002499A1
Authority
CL
Chile
Prior art keywords
pirrolidinilaminoacetilpirrolidinboronico
dpp
tartrate
sales
diabetes
Prior art date
Application number
CL200702499A
Other languages
English (en)
Inventor
Zhen-Ping Campbell David Al Wu
Original Assignee
Phenomix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corp filed Critical Phenomix Corp
Publication of CL2007002499A1 publication Critical patent/CL2007002499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL200702499A 2006-08-30 2007-06-27 Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. CL2007002499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84109706P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
CL2007002499A1 true CL2007002499A1 (es) 2008-03-14

Family

ID=39136484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702499A CL2007002499A1 (es) 2006-08-30 2007-06-27 Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.

Country Status (18)

Country Link
US (1) US8299271B2 (es)
EP (1) EP2061474A4 (es)
JP (1) JP5264728B2 (es)
KR (1) KR101504769B1 (es)
CN (1) CN101522201B (es)
AR (2) AR062590A1 (es)
AU (1) AU2007290684B2 (es)
BR (1) BRPI0715447B8 (es)
CA (1) CA2661776C (es)
CL (1) CL2007002499A1 (es)
EA (1) EA017833B1 (es)
HK (1) HK1134248A1 (es)
IL (2) IL197225A (es)
MX (1) MX2009002281A (es)
NO (1) NO20091291L (es)
TW (1) TW200817324A (es)
WO (1) WO2008027273A2 (es)
ZA (1) ZA200901510B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325903A1 (en) 2008-06-17 2009-12-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102286011B (zh) * 2010-03-16 2017-10-03 美德（江西）生物科技有限公司 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US20130289049A1 (en) * 2010-08-05 2013-10-31 Boehringer Ingelheim International Gmbh Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptorantagonists
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103483363B (zh) * 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
JP2014129255A (ja) * 2012-12-28 2014-07-10 Fujifilm Corp 組成物およびフィルムならびにそれらの製造方法
SG11201609259VA (en) 2014-05-20 2016-12-29 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
KR101978364B1 (ko) 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法
CN111533675B (zh) * 2019-11-29 2021-09-28 杭州华东医药集团新药研究院有限公司 杂环硼酸化合物的杂质及其控制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
BRPI0416444B8 (pt) * 2003-11-12 2021-05-25 Chiesi Farm Spa composto de ácido borônico heterocíclico, composição farmacêutica, e, combinação farmacêutica compreendendo o mesmo
AU2006275697A1 (en) * 2005-08-01 2007-02-08 Phenomix Corporation Methods of preparing hetercyclic boronic acids and derivatives thereof
EP2057143B1 (en) 2006-08-30 2013-07-24 Celgene Corporation 5-substituted isoindoline compounds
PE20080668A1 (es) 2006-08-30 2008-07-17 Novartis Ag Compuestos heterociclicos como inhibidores de la cinasa-2 de proteina activada por cinasa de proteina activada por mitogeno
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
EP2069286B1 (en) 2006-08-30 2012-09-19 F. Hoffmann-La Roche AG Inhibitors for glyt-1
CA2680133A1 (en) 2007-03-08 2008-09-12 David Alan Campbell Methods and intermediates for synthesis of selective dpp-iv inhibitors

Also Published As

Publication number Publication date
EA017833B1 (ru) 2013-03-29
CA2661776C (en) 2015-03-24
CN101522201A (zh) 2009-09-02
MX2009002281A (es) 2009-05-20
AU2007290684B2 (en) 2012-08-16
US20100323988A1 (en) 2010-12-23
IL197225A0 (en) 2009-12-24
WO2008027273A3 (en) 2008-07-31
IL242267A (en) 2017-12-31
TW200817324A (en) 2008-04-16
KR20090043601A (ko) 2009-05-06
IL197225A (en) 2015-11-30
JP2010502610A (ja) 2010-01-28
US8299271B2 (en) 2012-10-30
BRPI0715447B1 (pt) 2020-09-15
CN101522201B (zh) 2015-08-19
EA200900375A1 (ru) 2009-10-30
BRPI0715447A2 (pt) 2014-05-06
EP2061474A4 (en) 2011-06-15
JP5264728B2 (ja) 2013-08-14
NO20091291L (no) 2009-03-27
HK1134248A1 (zh) 2010-04-23
EP2061474A2 (en) 2009-05-27
KR101504769B1 (ko) 2015-03-20
AR062590A1 (es) 2008-11-19
CA2661776A1 (en) 2008-03-06
WO2008027273A2 (en) 2008-03-06
IL242267A0 (en) 2015-11-30
AU2007290684A1 (en) 2008-03-06
ZA200901510B (en) 2010-05-26
AR109135A2 (es) 2018-10-31
BRPI0715447B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CL2007002499A1 (es) Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2010032875A3 (en) Heterocyclic carboxamide compounds
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
BRPI0923217A2 (pt) processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
CL2007002686A1 (es) Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular.
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
AP2012006191A0 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same.
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP2103214A4 (en) FLOOR OR SEED TREATMENT AGENT CONTAINING A CHINOLINE COMPOUND OR A SALT THEREOF AS ACTIVE SUBSTANCE OR METHOD FOR COMBATING PLANT DISEASES USING THE AGENT
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
SMT201200014B (it) Nalmefene cloridrato diidrato.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
FR2910230B3 (fr) Methodes de biofertilisations pour ameliorer la stabilite des rendements de grandes cultures agronomiques.
PL1903030T3 (pl) Sposób katalitycznego wytwarzania aromatycznych lub heteroaromatycznych nitryli
BRPI0908168A2 (pt) composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes
CL2015000857A1 (es) Una composicion farmaceutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina; su metodo de preparacion, util para la prevencion y el tratamiento de la diabetes.
BRPI0719908A2 (pt) Forma cristalina, composto, uso de composto, formulação farmacêutica, método de tratamento de uma condição, e, processos para a produção de um composto cristalino e para a cristalização de um composto.
BRPI0808173A2 (pt) método para a produção de cloreto de ácido carboxílico.
EP2212325A4 (en) 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION